Tisagenlecleucel vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III BELINDA Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [31] Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Ansell, Stephen M.
    Witzig, Thomas E.
    Inwards, David J.
    Porrata, Luis F.
    Ythier, Arnaud
    Ferrande, Lee
    Nestorov, Ivan
    Devries, Todd
    Dillon, Stacey R.
    Hausman, Diana
    Novak, Anne J.
    CLINICAL CANCER RESEARCH, 2008, 14 (04) : 1105 - 1110
  • [32] Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
    Pan, Jonathan
    Ghimire, Sushil
    Alpdogan, S. Onder
    Chapman, Andrew
    Carabasi, Matthew
    DiMeglio, Martina
    Gong, Jerald
    Martinez-Outschoorn, Ubaldo
    Rose, Lewis
    Ramirez, Michael
    Wagner, John L.
    Weiss, Mark
    Flomenberg, Neal
    Pro, Barbara
    Porcu, Pierluigi
    Filicko-OHara, Joanne
    Gaballa, Sameh
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 590 - 597
  • [33] A PHASE III STUDY OF OFATUMUMAB VS RITUXIMAB IN INDOLENT B-CELL NON-HODGKIN LYMPHOMA RELAPSED AFTER RITUXIMAB CONTAINING THERAPY (HOMER): RESULTS OF THE INTERIM ANALYSIS
    Maloney, D. G.
    Fukuhara, N.
    Ogura, M.
    Larouche, J. F.
    Tournilhac, O.
    Coleman, M.
    Hong, X.
    Fennessy, M.
    Cota, M.
    Woessner, M.
    Tobinai, K.
    HAEMATOLOGICA, 2016, 101 : 102 - 102
  • [34] Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
    Schade, Jake R.
    Kim, Charles
    Drill, Esther
    Qiu, Annie
    Batlevi, Connie Lee
    Caron, Philip
    Colbourn, Donald Steven
    Hamilton, Audrey
    Hamlin, Paul A.
    Horwitz, Steven M.
    Intlekofer, Andrew M.
    Joffe, Erel
    von Keudell, Gottfried R.
    Kumar, Anita
    Noy, Ariela
    Okwali, Michelle
    Owens, Colette
    Palomba, M. Lia
    Rodriguez-Rivera, Ildefonso
    Sauter, Craig S.
    Schoder, Heiko
    Straus, David J.
    Vardhana, Santosha
    Younes, Anas
    Zelenetz, Andrew D.
    Matasar, Matthew J.
    BLOOD, 2019, 134
  • [35] Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Uchida, Toshiki
    Taniwaki, Masafumi
    Ando, Kiyoshi
    Watanabe, Takashi
    Kasai, Masanobu
    Matsumoto, Yosuke
    Shimizu, Daisuke
    Ogawa, Yoshiaki
    Ohmachi, Ken
    Yokoyama, Hiroki
    Tobinai, Kensei
    CANCER SCIENCE, 2010, 101 (09) : 2054 - 2058
  • [36] A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Itoh, Kuniaki
    Yamamoto, Kazuhito
    Au, Wing Yan
    Tien, Hwei-Fang
    Matsuno, Yoshihiro
    Terauchi, Takashi
    Yamamoto, Keiko
    Mori, Masahiko
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    Kim, Won Seog
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 768 - 776
  • [37] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoder, Heiko
    Ganesan, Nivetha
    Hancock, Helen
    Davey, Theresa
    Sohail, Samia
    Santarosa, Alayna
    Pomerantz, Lauren
    Jarjies, Christine
    Galasso, Natasha
    Neuman, Rachel
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Palomba, Maria Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 14 - 15
  • [38] Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan
    Schoder, Heiko
    Ganesan, Nivetha
    Hancock, Helen
    Davey, Theresa
    Sohail, Samia
    Santarosa, Alayna
    Pomerantz, Lauren
    Jarjies, Christine
    Galasso, Natasha
    Neuman, Rachel
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Falchi, Lorenzo
    Joffe, Erel
    Palomba, Maria Lia
    Noy, Ariela
    Matasar, Matthew J.
    Pongas, Georgios
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2020, 136
  • [39] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    Witzig, T. E.
    Vose, J. M.
    Zinzani, P. L.
    Reeder, C. B.
    Buckstein, R.
    Polikoff, J. A.
    Bouabdallah, R.
    Haioun, C.
    Tilly, H.
    Guo, P.
    Pietronigro, D.
    Ervin-Haynes, A. L.
    Czuczman, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627
  • [40] Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial
    Pettengell, Ruth
    Sebban, Catherine
    Zinzani, Pier Luigi
    Derigs, Hans Gunter
    Kravchenko, Sergey
    Singer, Jack W.
    Theocharous, Panteli
    Wang, Lixia
    Pavlyuk, Mariya
    Makhloufi, Kahina M.
    Coiffier, Bertrand
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (05) : 692 - 699
12345